Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)
- Authors:
- Stefan Langhammer
-
Affiliations: Life Science Consulting, Schloss Pesch, D‑40668 Meerbusch, Germany - Published online on: July 22, 2013 https://doi.org/10.3892/or.2013.2631
- Pages: 1535-1541
-
Copyright: © Langhammer . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
 |
|
Wang B, Rosano JM, Cheheltani R, Achary MP and Kiani MF: Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv. 7:1159–1173. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gilman A: The initial clinical trial of nitrogen mustard. Am J Surg. 105:574–578. 1963. View Article : Google Scholar : PubMed/NCBI | |
|
Papac RJ: Origins of cancer therapy. Yale J Biol Med. 74:391–398. 2001. | |
|
Dorr RT and Von Hoff DD: The Cancer Chemotherapy Handbook. 2nd edition. Appleton & Lange; East Norwalk, CT: pp. 51994 | |
|
Azzoli CG, Temin S and Giaccone G: 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 8:63–66. 2012. View Article : Google Scholar | |
|
Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W and Schmoll HJ: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 25:4217–4223. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Madi A, Fisher D, Wilson RH, Adams RA, Meade AM, Kenny SL, Nichols LL, Seymour MT, Wasan H, Kaplan R and Maughan TS: Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer. 107:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP and Earle CC: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 98:1108–1117. 2006. View Article : Google Scholar | |
|
Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG and Gietema JA: Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 10:391–399. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER Cancer Statistics Review, 1975–2009. Vintage 2009 Populations. National Cancer Institute; Bethesda, MD: 2012 | |
|
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D and Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 99:847–857. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapies for cancer 2004. Am J Clin Pathol. 122:598–609. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Swaby RF, Sharma CG and Jordan VC: SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord. 8:229–239. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005. | |
|
Grandis JR and Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 102:37–46. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Dutta PR and Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254:165–177. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Okamoto I: Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J. 277:309–315. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harandi A, Zaidi AS, Stocker AM and Laber DA: Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009:5674862009. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV: First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. J Thorac Oncol. 3:143–145. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI | |
|
Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
National Cancer Institute. Angiogenesis inhibitors. FactSheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors. Revised October 7, 2011. | |
|
Heath VL and Bicknell R: Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 6:395–404. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ivy SP, Wick JY and Kaufman BM: An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 6:569–579. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jayson GC, Hicklin DJ and Ellis LM: Antiangiogenic therapy - evolving view based on clinical trial results. Nat Rev Clin Oncol. 9:297–303. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ebos JM and Kerbel RS: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oudard S, Beuselinck B, Decoene J and Albers P: Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev. 37:178–184. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tanne JH: FDA cancels approval for bevacizumab in advanced breast cancer. BMJ. 343:d76842011. View Article : Google Scholar : PubMed/NCBI | |
|
Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN and Chabner BA: Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 13:6719–6726. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yarden Y: The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer. 37:S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Buller RM, Chakrabarti S, Moss B and Fredrickson T: Cell proliferative response to vaccinia virus is mediated by VGF. Virology. 164:182–192. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Langhammer S, Koban R, Yue C and Ellerbrok H: Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antiviral Res. 89:64–70. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou RS, Gallo RC and Wong-Staal F: Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses. 3:57–69. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Perelson AS, Neumann AU, Markowitz M, Leonard JM and Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1582–1586. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell TB, Schneider K, Wrin T, Petropoulos CJ and Connick E: Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol. 77:12105–12112. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:123–126. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hemelaar J: The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 18:182–192. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Klein CA: Parallel progression of primary tumors and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Greaves M and Maley CC: Clonal evolution in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Merlo LM, Pepper JW, Reid BJ and Maley CC: Cancer as an evolutionary and ecological process. Nat Rev Cancer. 6:924–935. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS and Reid BJ: Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 38:468–473. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pepper J, Findlay CS, Kassen R, Spencer S and Maley CC: Cancer research meets evolutionary biology. Evol Appl. 2:62–70. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
González-García I, Solé RV and Costa J: Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA. 99:13085–13089. 2002. | |
|
Staveley-O’Corrol K, Sotomayor E, Mongomery J, Borrello I, Hwang L, Fein S, Pardoll D and Levitsky H: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 95:1178–1183. 1998.PubMed/NCBI | |
|
Finke J, Ferrone S, Frey A, Mufson A and Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 20:158–160. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Levy LS: Retrovirus-induced immunodeficiency and cancer. Retroviruses and Insights into Cancer. Dudley J: Springer; New York: pp. 259–283. 2011 | |
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD and Goulder PJ: HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 10:282–289. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Klenerman P, Wu Y and Phillips R: HIV: current opinion in escapology. Curr Opin Microbiol. 5:408–413. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D and Yu H: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H, Hiddingh L, Kroon J, van den Eertwegh AJ, Hangalapura B, Scheper RJ and de Gruijl TD: Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology. 1:649–658. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CA, Phillips AN, Elford J, Janossy G, Griffiths P and Kernoff P: Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment. BMJ. 303:1093–1096. 1991.Erratum in: BMJ 303: 1446, 1991. | |
|
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS and Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 335:1081–1090. 1996. View Article : Google Scholar | |
|
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA and Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 337:725–733. 1997. View Article : Google Scholar | |
|
Leung D, Abbenante G and Fairlie DP: Protease inhibitors: current status and future prospects. J Med Chem. 43:305–341. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM and Egger M; Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 366:378–384. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Saif MW, Katirtzoglou NA and Syrigos KN: Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 19:447–464. 2008.PubMed/NCBI | |
|
Hatziveis K, Tourlakis D, Hountis P, Kyriazanos I, Sougleri M, Ginopoulos P and Camoutsis C: Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III–IV ovarian and non-small cell lung cancer and its role in survival and toxicity. J BUON. 17:143–148. 2012.PubMed/NCBI | |
|
Li T, Kung HJ, Mack PC and Gandara DR: Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 31:1039–1049. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 12:713–718. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw AT, Solomon B and Kenudson MM: Crizotinib and testing for ALK. J Natl Compr Canc Netw. 9:1335–1341. 2011.PubMed/NCBI | |
|
Takahashi S: Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Doi Y, Yashiro M, Yamada N, Amano R, Noda S and Hirakawa K: VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol. 19:2733–2743. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM and Pryer NK: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with ‘standard of care’ therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2:1011–1021. 2003. | |
|
Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Burger JA, Stewart DJ, Wald O and Peled A: Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 11:621–630. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao BC, Wang ZJ, Mao WZ, Ma HC, Han JG, Zhao B and Xu HM: CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol. 17:2389–23896. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hou KL, Hao MG, Bo JJ and Wang JH: CXCR7 in tumorigenesis and progression. Chin J Cancer. 29:456–459. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ and Burger JA: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 22:8093–80101. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Soriano SF, Serrano A, Hernanz-Falcón P, Martín de Ana A, Monterrubio M, Martinez C, Rodríguez-Frade JM and Mellado M: Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses. Eur J Immunol. 33:1328–1333. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE and Salgia R: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI | |
|
D’Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, Ieranò C, Franco R, Scognamiglio G, Bryce J, Luciano A, Rea D, Arra C and Scala S: Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother. 61:1713–1720. 2012.PubMed/NCBI | |
|
Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC and Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma M, Afrin F, Satija N, Tripathi RP and Gangenahalli GU: Stromal-derived factor-1/CXCR4 signaling: indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev. 20:933–946. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
D’Alterio C, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G and Scala S: High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets. 12:693–702. 2012.PubMed/NCBI | |
|
Zhao HB, Tang CL, Hou YL, Xue LR, Li MQ, Du MR and Li DJ: CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells. PLoS One. 7:e383752012. View Article : Google Scholar : PubMed/NCBI | |
|
Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 71:1623–1647. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E and Olivieri A: Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 18:241–249. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li JK, Yu L, Shen Y, Zhou LS, Wang YC and Zhang JH: Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol. 14:2308–2313. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Garnier D, Magnus N, D’Asti E, Hashemi M, Meehan B, Milsom C and Rak J: Genetic pathways linking hemostasis and cancer. Thromb Res. 129(Suppl 1): S22–S29. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nakanishi M, Sato T, Li Y, Nelson AJ, Farid M, Michalski J, Kanaji N, Wang X, Basma H, Patil A, Goraya J, Liu X, Togo S, Toews LM, Holz O, Muller KC, Magnussen H and Rennard SI: Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fibroblasts. Am J Respir Cell Mol Biol. 46:217–223. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H, Chen Z, Jin H, Zhuang M, Wang T, Su C, Lei Y, Zou J and Zhong B: Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. J Exp Clin Cancer Res. 30:62011. View Article : Google Scholar : PubMed/NCBI | |
|
Obermajer N, Muthuswamy R, Odunsi K, Edwards RP and Kalinski P: PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71:7463–7470. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shimada K, Anai S, Marco DA, Fujimoto K and Konishi N: Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival. BMC Urol. 11:82011.PubMed/NCBI | |
|
Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem. 279:29797–29804. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schönthal AH: Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anticancer Agents Med Chem. 10:450–461. 2010.PubMed/NCBI |
